Roundtable Discussion; The Future of Mineral Sands. Watch the video here.
Agreed leggster definitely a possibility and the one possible scenario I’m leaning more towards. We will have comparative safety data against brepocitinib with P1a as John stated here: https://youtu.be/1x1_ktQPLik?feature=shared&t=3474 and a bonus their P1 data is published for investors to see.
Looking back through the Edison report from last March which is normally balanced & fair on its bull / bear stated: “We see initiation of the Phase I study as a key catalyst for a potential re-rating” at the time the SP was 87.5p rising to 149.00p since July the share price has done nothing but fall even with additional positives; 3 patents granted, SRA737 on-licensed and good progress so far with SDC-1801 P1a. There is huge disconnect here and opportunity for new money, it will turn...… GLA
Come on US Private Biotech put our CHK1 in the limelight and let’s start to have some of our $80m milestone payments. Our Mk Cap is such a joke right now….
Clinical-stage CHK1 inhibitors /
https://www.oncologypipeline.com/apexonco/boundless-enthusiasm-chk1
If they raise over $50m they may appear in the link below it updates daily; https://www.fiercebiotech.com/biotech/fierce-biotech-fundraising-tracker-24
Amended terms of a 2016 licensing agreement between Sierra Oncology Inc and CRT Pioneer Fund LP (CPF) for SRA737.
The AIM-listed drug development firm said under the 2016 agreement SRA737 was licensed to Sierra by CPF for up to US$328.5mln in developmental, regulatory and commercial milestones, plus royalties on the net sales of any product successfully developed. Sareum was eligible to receive 27.5% of the economics equating to up to US$88mln in milestone payments, plus sales royalties, as SRA737 advanced.
Under the terms of the original agreement, additional payments of up to an aggregate of US$319.5mln were payable to CPF upon the achievement of certain milestones, including a milestone payment of US$7.5mln upon the dosing of the first patient in the first Phase 1 trial of SRA737 in the US, and a payment of US$12mln upon the dosing of the first patient of a randomised Phase 2 trial of SRA737.
Under the amended agreement, Sareum and CPF have agreed to a decrease in the additional milestone payments of up to US$290mln that may be payable to CPF upon the achievement of certain milestones, including a milestone payment of US$2mln upon the dosing of the first patient of the first trial of SRA737 following the amendment
Agree with that SOG there's definitely a strong resurgence with Pharma and CHK1 and believe the BOD were truthful when they said interested parties where queuing up. Exciting times ahead for both SRA737 & SDC-1801 GLA
Nice find HBD, additional SRA737 + low-dose hydroxyurea reading:
SRA737 Checkpoint kinase 1 inhibitor + low-dose hydroxyurea efficiently kills BRAF inhibitor- and immune checkpoint inhibitor-resistant melanomas:
https://onlinelibrary.wiley.com/doi/10.1111/pcmr.13120?af=R
Positive news in CSU for TYK2 / JAK1 inhibitors, not long now until SDC-1801 enters the arena exciting times clocks ticking….https://www.rheuma.com.au/can-a-new-jak-inhibitor-help-hives/26235
When looking at TLL-018 we had early data against tofacitinib: https://journals.aai.org/jimmunol/article/193/7/3278/98480/Inhibition-of-TYK2-and-JAK1-Ameliorates-Imiquimod
Unusual for an MM not to move, usually a NT trade will move them like the one earlier at 0.36 strange although a couple of chunky NT buys should clear them if not they will clear at the end of play.
Could be the RF 5 day VWAP in play /
I think I had the trial ending (MAD) around the 4th March but give or take a week or so news is getting very close which in turn should be the green light for the RF drawdown. Not concerned if it’s short by a few hundred k that really shouldn’t be a problem going forwards with essentially SDC-1801 being a P2 asset at that point. Taking note of Sudo has just secured $147m to progress their preclinical Tyk2’s into P1 trials.
GLA
They were aware when they took the RF finance that the 4th deposit carried conditions. They really do need to be proactive now to stop this continual decimation of the SP; LTH’s are exhausted trying to support the declining share price / market cap, even the markets are blind to the state of play with SDC-1801 & SRA737 so without imminent news it’s up to the Bod to step up….
Sunday musings.
The Twists and Turns in Biopharma Dealmaking 2024: https://www.pharmexec.com/view/twists-turns-biopharma-dealmaking-2024-trends
Merck's latest deal turns up the spotlight on immune system drugmakers. The buyout of Prometheus highlights pharmaceutical companies' intense interest in medicines targeting inflammatory diseases: https://www.biopharmadive.com/news/biotech-deals-immunology-acquisitions-merck-prometheus/647802/
-----------------------------
SRA737 reminder: https://s28.q4cdn.com/726829854/files/doc_downloads/events/ASCO-SRA737-Analyst-Call-Presentation_final.pdf
Proof-of-concept activity in multiple indications
Anti-cancer activity correlated with genetics
Very promising anogenital cancer signal
Anogenital cancer: tractable opportunity to potentially pursue registration-intent studies
- unmet medical need; low historical ORR/PFS in 2L
- substantial potential market opportunity
- anogenital P2 cost estimated at $10M
PARPi & IO combinations provide compelling additional opportunities
I don’t think for a minute the CPF would re license SRA737 without the licensee providing a full rationale of moving it forward at pace especially after the delays it suffered under Sierra. Any interested parties have had access to SRA737 to run any pre clinical combinations prior to licensing. It’s P3 ready and looks extremely promising in many combination trials. IMO we will hear something as soon as funding is in place and they have had it coming up 2 months now….
Agreed but its fluid what the bod considers attractive before the end of P1b vs LTH’s is another matter either way we are in the end game so GLA.
Annual Report 2024 objectives: License drug candidates to pharmaceutical company partners
Once the planned Phase 1b clinical trial of SDC-1801 is completed, expected by end of calendar year 2024, we believe we will have a comprehensive clinical data package that should be attractive to potential licence partners.
However, we will maintain our dialogues with potential partners and, should the opportunity for an attractive licence deal arise before the completion of this Phase 1b, we would give it serious consideration.
If 1a data shows SDC-1801 can be administered at a higher dosage than (Brepocitinib 30–60mg) with the same or better safety profile IMO we won’t even make it to 1b before a license deal or a T/O happens…. RF Redundant means to an end /
Best Guess MMs marking the bottom... nothing surprises me here /
Still believe the directors have a big opportunity to buy large now and put the sentiment back, you see it all the time on the Nasdaq before big news takeovers etc